Treatment effect of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma aiming at curative conversion therapy

被引：0
|
作者：
Tomonari, Tetsu [1 ]
Tani, Joji [2 ]
Sato, Yasushi [1 ]
Tanaka, Hironori [1 ]
Taniguchi, Tatsuya [1 ]
Kawano, Yutaka [1 ]
Masaki, Tsutomu [2 ]
Takayama, Tetsuji [1 ]
机构：
[1] Dept Gastroenterol & Oncol, Tokushima, Japan
[2] Dept Gastroenterol & Neurol, Takamatsu, Kagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO6-6
引用
收藏
页码：S1399 / S1399
页数：1
相关论文
共 50 条
  • [1] Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma
    Komatsu, Shohei
    Yano, Yoshihiko
    Kido, Masahiro
    Kuramitsu, Kaori
    Gon, Hidetoshi
    Fukushima, Kenji
    Urade, Takeshi
    So, Shinichi
    Yamamoto, Atsushi
    Goto, Tadahiro
    Yanagimoto, Hiroaki
    Toyama, Hirochika
    Ueda, Yoshihide
    Kodama, Yuzo
    Fukumoto, Takumi
    ANTICANCER RESEARCH, 2022, 42 (11) : 5479 - 5486
  • [2] Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients
    Toshida, Katsuya
    Itoh, Shinji
    Tomiyama, Takahiro
    Morinaga, Akinari
    Kosai, Yukiko
    Tomino, Takahiro
    Kurihara, Takeshi
    Nagao, Yoshihiro
    Morita, Kazutoyo
    Harada, Noboru
    Yoshizumi, Tomoharu
    JGH OPEN, 2022, 6 (07): : 477 - 486
  • [3] Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
    Yano, Shigeki
    Kawaoka, Tomokazu
    Johira, Yusuke
    Miura, Ryoichi
    Kosaka, Masanari
    Shirane, Yuki
    Murakami, Serami
    Amioka, Kei
    Naruto, Kensuke
    Ando, Yuwa
    Kosaka, Yumi
    Yamaoka, Kenji
    Kodama, Kenichiro
    Uchikawa, Shinsuke
    Fujino, Hatsue
    Ohno, Atsushi
    Nakahara, Takashi
    Murakami, Eisuke
    Okamoto, Wataru
    Yamauchi, Masami
    Imamura, Michio
    Mori, Keiichi
    Arihiro, Kouji
    Kuroda, Shintaro
    Kobayashi, Tsuyoshi
    Ohdan, Hideki
    Aikata, Hiroshi
    MEDICINE, 2021, 100 (42) : E27576
  • [4] Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab
    Kikuchi, Tatsuya
    Takeuchi, Yasuto
    Nouso, Kazuhiro
    Kariyama, Kazuya
    Kuwaki, Kenji
    Toshimori, Junichi
    Iwado, Shota
    Moriya, Akio
    Hagihara, Hiroaki
    Takabatake, Hiroyuki
    Tada, Toshifumi
    Yasunaka, Tetsuya
    Sakata, Masahiro
    Sue, Masahiko
    Miyake, Nozomi
    Adachi, Takuya
    Wada, Nozomu
    Onishi, Hideki
    Shiraha, Hidenori
    Takaki, Akinobu
    Otsuka, Motoyuki
    LIVER INTERNATIONAL, 2024, 44 (06) : 1456 - 1463
  • [5] The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Shimose, Shigeo
    Iwamoto, Hideki
    Shirono, Tomotake
    Tanaka, Masatoshi
    Niizeki, Takashi
    Kajiwara, Masahiko
    Itano, Satoshi
    Yano, Yoichi
    Matsugaki, Satoru
    Moriyama, Etsuko
    Noda, Yu
    Nakano, Masahito
    Kuromatsu, Ryoko
    Koga, Hironori
    Kawaguchi, Takumi
    CANCER MEDICINE, 2023, 12 (11): : 12325 - 12335
  • [6] Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
    Hongyu Gong
    Siew Chin Ong
    Fan Li
    Zhiying Weng
    Keying Zhao
    Zhengyou Jiang
    Cost Effectiveness and Resource Allocation, 21
  • [7] Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
    Kudo, Masatoshi
    HEPATOBILIARY SURGERY AND NUTRITION, 2023, 12 (03) : 435 - 439
  • [8] Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
    Gong, Hongyu
    Ong, Siew Chin
    Li, Fan
    Weng, Zhiying
    Zhao, Keying
    Jiang, Zhengyou
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [9] Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series
    Ichimura, Takenori
    Ichikura, Daisuke
    Hinata, Miwa
    Hida, Noriko
    Baba, Toshiyuki
    SAGE OPEN MEDICAL CASE REPORTS, 2023, 11
  • [10] Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
    Yano, Shigeki
    Kawaoka, Tomokazu
    Yamasaki, Shintaro
    Johira, Yusuke
    Kosaka, Masanari
    Shirane, Yuki
    Miura, Ryoichi
    Amioka, Kei
    Naruto, Kensuke
    Yamaoka, Kenji
    Fujii, Yasutoshi
    Uchikawa, Shinsuke
    Fujino, Hatsue
    Ono, Atsushi
    Nakahara, Takashi
    Murakami, Eisuke
    Miki, Daiki
    Tsuge, Masataka
    Teraoka, Yuji
    Kouno, Hirotaka
    Takaki, Shintaro
    Mori, Nami
    Tsuji, Keiji
    Oka, Shiro
    CANCERS, 2023, 15 (22)
12345